Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
7 Results for "
soluble extracellular domain
" in MedChemExpress (MCE) Product Catalog:
Products (7)
7 Results for "soluble extracellular domain" in MCE Product Catalog:
3
3 Cited Publications
Synonyms: CTLA4lg; BMS-188667
Target:
Research Areas:
3
3 Cited Publications
Synonyms: CTLA4lg (powder); BMS-188667 (powder); Orencia
Target:
Research Areas:
Cat. No.: HY-P99729
CAS No.: 2222865-46-3
Synonyms: GSK 3772847; CNTO-7160
Target:
Research Areas:
Cat. No.: HY-145775
CAS No.: 1425051-22-4
Target:
Research Areas:
hIgG-hFc receptor-IN-1 is a quinoxaline-based human immunoglobulin G-human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction inhibitor with an IC50 of 2 μM. hIgG-hFc receptor-IN-1 blocks the binding of hIgG to human FcRn. hIgG-hFc receptor-IN-1 can be used for immune-related research .
Cat. No.: HY-187393
CAS No.: 1425051-06-4
Target:
Research Areas:
hIgG-hFc receptor-IN-2 is a hFcRn inhibitor with an IC50 of 6 μM for human hFcRn. hIgG-hFc receptor-IN-2 blocks the protein-protein interaction between human IgG and the soluble extracellular domain of hFcRn. hIgG-hFc receptor-IN-2 serves as a tool for studying FcRn biology and a starting point for developing orally available small molecule hFcRn inhibitors. hIgG-hFc receptor-IN-2 can be used for the research of autoimmune disease .
Cat. No.: HY-182980
Research Areas:
N-(8-Carboxyoctanoyl)-deacetyl BMS-202 is a target protein ligand-linker conjugate. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 contains the target protein PD-1/PD-L1 ligand and a PROTAC linker. N-(8-Carboxyoctanoyl)-deacetyl BMS-202 can be used for the synthesis of PROTAC PD-L1 Degrader-3 (HY-182959) .
Cat. No.: HY-184378
CAS No.: 2922221-22-3
Target:
Research Areas:
MDB5 is a Hedgehog pathway and Smoothened inhibitor that binds to the 7-TM domain of Smo . MDB5 reduces hepatic stellate cell activation, extracellular matrix-related gene expression, collagen deposition, hydroxyproline content and epithelial-mesenchymal transition, and prevents sinusoidal endothelial cell capillarization . MDB5 induces G1 and S phase cell cycle arrest, triggers apoptosis by upregulating Bax and downregulating Bcl-2, and also decreases oxygen consumption rate, glucose uptake, transglutaminase activity and fibronectin matrix assembly . MDB5 reduces the levels of liver injury markers, hepatic triglyceride deposition and hepatic steatosis, restores the tissue structure of the kidney and spleen, and inhibits pancreatic tumor growth without causing body weight loss . MDB5 can be loaded into PEG-PCC-g-DC micelles, achieving high drug loading, sustained release, improved water solubility, enhanced cellular uptake and optimized hepatic distribution, with good tolerance in mice . MDB5 is applicable to research related to alcohol-associated liver disease, liver fibrosis and pancreatic cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
